Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.42 |
| ▸ | JAK1 | P23458 | 10/20 | 0.42 |
| ▸ | TYK2 | P29597 | 3/20 | 0.42 |
| ▸ | JAK2 | O60674 | 9/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22736159 | 0.81 | GRM4 (0.45) | JAK3JAK1TYK2JAK2GRM4 | |
| SCHEMBL29567533 | 0.78 | EGLN1 (0.36) | JAK3JAK1TYK2JAK2GRM4 | |
| SCHEMBL22735720 | 0.78 | EGLN1 (0.36) | JAK3JAK1TYK2JAK2GRM4 | |
| SCHEMBL29480583 | 0.74 | JAK2 (0.40) | JAK3JAK1TYK2JAK2 | |
| SCHEMBL22736087 | 0.74 | GRM4 (0.39) | JAK3JAK1TYK2JAK2GRM4 | |
| SCHEMBL29480577 | 0.74 | GRM4 (0.39) | JAK3JAK1TYK2JAK2GRM4 | |
| SCHEMBL29480526 | 0.74 | GRM4 (0.44) | GRM4HTR2BMTNR1AKCNH2 | |
| SCHEMBL22716872 | 0.74 | GRM4 (0.44) | GRM4HTR2BMTNR1AKCNH2 | |
| SCHEMBL22736178 | 0.74 | JAK2 (0.36) | JAK3JAK1TYK2JAK2GRM4 | |
| SCHEMBL22736154 | 0.72 | GRM4 (0.41) | JAK1JAK2GRM4HTR2BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976612-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD (IN) | 2022-04-06 | — | — | EP | claimed |
| CN-114174294-A | Novel compounds for inhibiting JANUS kinase 1 | 人类制药有限公司 | 2022-03-11 | — | — | CN | claimed |
| US-12516056-B2 | Compounds for inhibition of janus kinase 1 | MANKIND PHARMA LTD. (IN) | 2026-01-06 | — | — | US | disclosed |
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2022-07-28 | — | — | US | disclosed |
| WO-2020240586-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | JAK1, JAK2, JAK3 | JAK3 3/4885JAK1 1/4885TYK2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.